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Benzodiazepines(BDZs)areknowntoincreasetheamplitudeanddurationofIPSCs.Moreover,
at low [GABA], BDZs strongly enhance GABAergic currents suggesting the up-regulation
of agonist binding while their action on gating remains a matter of debate. In the present
study we have examined the impact of ﬂurazepam and zolpidem on mIPSCs by investigating
theireffectsonGABAARbindingandgatingandbyconsideringdynamicconditionsofsynaptic
receptor activation. Flurazepam and zolpidem enhanced the amplitude and prolonged decay
of mIPSCs. Both compounds strongly enhanced responses to low [GABA] but, surprisingly,
decreased the currents evoked by saturating or half-saturating [GABA]. Analysis of current
responses to ultrafast GABA applications indicated that these compounds enhanced binding
and desensitization of GABAA receptors. Flurazepam and zolpidem markedly prolonged
deactivation of responses to low [GABA] but had almost no effect on deactivation at saturating
or half-saturating [GABA]. Moreover, at low [GABA], ﬂurazepam enhanced desensitization–
deactivationcouplingbutzolpidemdidnot.Recordingsofresponsestohalf-saturating[GABA]
applications revealed that appropriate timing of agonist exposure was sufﬁcient to reproduce
eitheradecreaseorenhancementofcurrentsbyﬂurazepamorzolpidem.Recordingsofcurrents
mediatedbyrecombinant(‘synaptic’)α1β2γ2receptorsreproducedallmajorﬁndingsobserved
for neuronal GABAARs. We conclude that an extremely brief agonist transient renders IPSCs
particularly sensitive to the up-regulation of agonist binding by BDZs.
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GABA (γ-aminobutyric acid) is the major inhibitory
neurotransmitterintheadultmammaliancentralnervous
system. To date, as many as 20 subunits of GABAA
receptors (γ-aminobutyric acid receptor type A) (α1–6,
β1–4, γ1–3, δ, ρ1–3, ε, π and θ)h a v eb e e nc l o n e d
(Cherubini & Conti, 2001; Fritschy & Brunig, 2003)
suggestinganoverwhelmingheterogeneity.However,most
commonGABAARsconsistoftwoα,twoβ andoneγ orδ
subunit (Whiting, 2003; Wafford, 2005).
Benzodiazepine (BDZ) receptor agonists are known
as positive modulators of speciﬁc GABAA receptors
(GABAARs) (Rudolph & Mohler, 2004; Wafford, 2005;
Rudolph&Mohler,2006).BDZswerecommonlyfoundto
enhance the amplitude and to prolong GABAergic IPSCs
(inhibitory postsynaptic currents) (Frerking et al. 1995;
Nusseretal.1997;Perrais&Ropert,1999;Hajosetal.2000;
Perrais & Ropert, 2000). Several lines of evidence indicate
that BDZs up-regulate the binding afﬁnity of GABAARs.
A compelling indication for this mechanism is a strong
BDZ-induced enhancement of amplitude and onset rate
of currents evoked by non-saturating [GABA] but these
effects tend to disappear at saturating [GABA] (Lavoie &
Twyman, 1996; Krampﬂ et al. 1998). BDZs do not clearly
affecttheGABAARsinglechannellifetimes(Twymanetal.
1989; Rogers et al.1994). These ﬁndings, taken altogether,
suggest that BDZs enhance binding afﬁnity while their
effect on GABAAR gating appears minor. However, Rusch
& Forman (2005) as well as Downing et al. (2005) have
proposedanovelmechanismforGABAARmodulationby
BDZs. They considered a spontaneously active GABAAR
mutantandreportedthatBDZsmighteffectivelymodulate
the GABAAR gating. However, it was not clear to what
extent these observations applied to the native GABAARs
in which coupling between binding and gating has not
been altered by mutations. More recently, Campo-Soria
et al. (2006) have reported that in oocytes expressing
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ultrahigh levels of wild type GABAA receptors, a high
concentration (1μm) of diazepam induced a small but
detectable GABAergic current and proposed that this
BDZ might act on GABAARs by affecting the opening
transitions. In a recent study, we have reported that
ﬂurazepamandzolpidemaffectedbothbindingandgating
of α1β2γ2 receptors (Mercik et al. 2007). The effect
on receptor gating was deduced from a BDZ-induced
decrease in amplitude and a moderate modulation of the
time course of currents elicited by saturating [GABA].
These observations appeared peculiar as they were
substantially different from what is commonly observed
for synaptic currents. It is thus interesting to investigate
whether the effects of ﬂurazepam and zolpidem observed
for α1β2γ2 receptors can be reproduced in neurons. In
particular, it is appealing to compare the action of these
drugs on currents evoked by exogenous GABA and on
mIPSCs(miniatureinhibitorypostsynapticcurrents).For
this purpose, the effect of ﬂurazepam and zolpidem has
been examined on mIPSCs and on current responses
to ultrafast GABA applications recorded from rat
culturedhippocampalneurons.Wefoundthatﬂurazepam
and zolpidem modulated both binding and gating of
neuronal receptors. However, BDZ effects on amplitudes
ofmIPSCsandonresponsestosaturating[GABA]showed
qualitative differences. To explore this discrepancy, we
have modelled the synaptic currents by responses to short
applications of non-saturating [GABA] and concluded
that extreme non-equilibrium conditions, dictated by
a fast agonist transient, render mIPSCs particularly
susceptible to modulation by BDZs.
Methods
Neuronal primary cell culture
Primary cell culture was prepared as already described
(Andjus et al. 1997). Brieﬂy, P2–P4 Wistar rats were killed
by decapitation. This procedure is in agreement with the
Polish Animal Welfare Act and has been approved by the
Local Ethical Commission. Hippocampi were dissected,
sliced, treated with trypsin, mechanically dissociated and
centrifuged twice at 40g, plated in Petri dishes and
cultured. Experiments were performed on cells between
10 and 15days in culture.
Expression of recombinant receptors
The recombinant α1β2γ2S GABAA receptors were
expressed in the HEK293 cell line (human embryonic
kidney cells). HEK293 cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium with Glutamax-I (Gibco BRL)
supplemented with 5% fetal bovine serum (Gibco BRL),
100Uml−1 penicillin G, and 100μgml −1 streptomycin
in an incubator at 37◦C with 5.0% CO2. Transfection
was performed using a standard calcium phosphate
precipitation protocol (Chen & Okayama, 1987) with
plasmids pGW1 ampicillin-resistant containing cDNA
encoding for rat α1, β2, γ2S or GABAA receptor.
Plasmids were cotransfected at individual concentrations
of 1μgml −1 together with the pCVMCD4 plasmid
to encode the CD4 receptor. Transfected cells were
identiﬁedbymarkers(beads)coveredwithanti-CD4anti-
bodies(DynabeadsM–450CD4,DynalBiotechASA,Oslo,
Norway).
Electrophysiological recordings
Currents were recorded either from neurons or from
HEK293 cells in the outside-out mode of the patch-clamp
technique using the Axopatch200B ampliﬁer (Molecular
Device Corporation, Sunnyvale, CA, USA) at −70mV.
The intrapipette solution contained: (mm) 137 CsCl,
1 CaCl2, 2 MgCl2, 11 BAPTA (tetracaesium salt), 2
ATP and 10 Hepes, pH7.2 with CsOH. The external
solution was composed of (mm): 137 NaCl, 5 KCl, 2
CaCl2, 1 MgCl2, 20 glucose and 10 Hepes, pH7.2 with
NaOH. The current signals were ﬁltered at 10kHz with
a Butterworth ﬁlter, sampled at 50–100kHz, using the
analog-to-digital converter Digidata 1322A (Molecular
Device Corporation) and stored on the computer
hard disk. pCLAMP9.2 (Molecular Device Corporation)
software was used for acquisition and data analysis.
Miniature synaptic currents were recorded in the
whole-cell conﬁguration of the patch clamp technique
in the presence of 1μm tetrodotoxin (TTX). Current
responses to 1μm GABA were barely detectable in the
excised patch conﬁguration and for this reason were
recordedinthewhole-cellmodeusingamultibarrelsystem
(RSC-200, Bio-Logic, Grenoble, France; exchange time
ca 8–15ms). In most cases, responses to 3μm GABA
obtainedfromexcisedpatchesweretoosmalltobereliably
analysedandthereforemostoftheresponsestothisGABA
concentration were collected in the whole-cell mode as in
the case of 1μm GABA.
Rapid drug application
GABA was applied to excised patches using the
ultrafast perfusion system based on a piezoelectric-driven
theta-glass application pipette (Jonas, 1995). The
piezoelectric translator was from Physik Instrumente
(preloaded HVPZT translator 80μm, Waldbronn,
Germany) and theta-glass tubing was from Hilgenberg
(Malsfeld,Germany).Theopentiprecordingsoftheliquid
junction potentials revealed that 10–90% exchange of
solution occurred within 50–80μs. A minimum duration
of drug application was 0.8–1ms (at shorter pulses,
often oscillations appeared). In experiments in which
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the effect of BDZ receptor agonists was examined, the
tested modulator was present at the same concentrations
in solutions supplied by both channels (wash and
GABA-containing solution) of the theta-glass capillary.
Before applying the agonist (in the presence or absence
of BDZ) the patch was exposed to the washing solution
foratleast2min.Occasionally,incellswithhighGABAAR
expression,currentresponsesto3μmGABAwerestudied
in the excised patches using ultrafast perfusion. The
current characteristics such as rise time and deactivation
of responses recorded in the whole-cell and excised-patch
modeswerenotclearlydifferent.Duetoextremedifﬁculty
of experiments with ultrafast application system we have
focused our study on testing the effects of ﬂurazepam and
zolpidem at micromolar concentrations that were close to
saturation for both drugs (e.g. Tietz et al. 1999; Walters
et al. 2000). For responses to low [GABA] (1–3μm), 1μm
of ﬂurazepam or zolpidem yielded a submaximal effect
that reached saturation at 3μm (zolpidem) or between 3
and 10μm (ﬂurazepam, data not shown).
Data analysis
The kinetics of the current rising phase was quantiﬁed as
10–90% rise time. Deactivation current was ﬁtted with a
sum of two exponential functions:
y(t) = A1 exp(−t/τfast) + A2 exp(−t/τslow)
whereA1andA2arethepercentageswhileτfastandτsloware
the time constants. For normalized currents, A1 +A2 =1.
The mean time constant was calculated as τmean =A1τfast
+ A2τslow. The desensitization kinetics was described by
a sum of one exponential function and a constant value
representing the steady-state current. Recovery parameter
R was deﬁned as R =(I2 −I3)/(I1 −I3), where I1 the
ﬁrst peak amplitude, I2 the second peak amplitude, and
I3 is the current immediately before the second pulse.
The effect of ﬂurazepam and zolpidem on IPSCs and
on current responses was assessed from the comparison
betweencontrolandtestrecordingsfromthesamecell(or
excised patch). For this reason all the results are presented
as relative values normalized to the respective controls.
The kinetic modelling was performed using the
ChannelLab2.0 software (developed by S. Traynelis for
Synaptosoft,Decatour,GA,USA).Thissoftwareconverted
the kinetic model into a set of differential equations and
solvedthemnumericallyassuming,astheinitialcondition,
thatatt = 0(wheret istime),noboundoropenreceptors
werepresent.Thesolutionofsuchequationspredictedthe
timecoursesofoccupanciesofallthestatesincludedinthe
model. The current time course was modelled as the time
evolution of the sum of open state occupancies.
Dataareexpressedasmean±s.e.m.andStudent’st test
was used for the comparison of data.
All experiments were performed at room temperature
(22–24◦C).
Results
Flurazepam and zolpidem enhance amplitude
and slow down the decaying phase of mIPSCs
Miniature IPSCs were recorded in the whole-cell
conﬁguration at −70mV in the presence of 1μm TTX
(Fig.1A). On average, in control conditions, mIPSC
amplitude was −41.21±2.22pA (n=21). The averaged
mIPSCfrequencyincontrolconditionswas0.26±0.02Hz
(n=21) and it was not signiﬁcantly affected by either
ﬂurazepam or zolpidem (data not shown). Addition
of ﬂurazepam resulted in a signiﬁcant increase in
the mean mIPSC amplitude for the entire range of
considered ﬂurazepam concentrations (1–10μm, Fig.1B)
and in a clear shift in the cumulative amplitude
distribution (Fig.1C). With 1μm ﬂurazepam, the relative
amplitudewas1.20±0.06(n=11).Similarly,zolpidemat
concentrations of 0.3–3μm, signiﬁcantly enhanced mean
mIPSC amplitudes (Fig.1D and E;a t1μm zolpidem, the
relative amplitude increase was 1.23±0.07, n=6).
The ﬂurazepam-induced increase in mIPSC amplitude
was accompanied by a change in the current kinetics.
In control conditions, the decaying phase of mIPSCs
could be well ﬁtted with a sum of two exponentials
(τfast =11.83±1.06ms, τslow =61.37±3.8ms, Aslow =
0.46±0.03, n=11) and the mean decay time constant
was τmean =36.28±1.92ms. As shown in Fig.2B, the
value of τmean was increased by ﬂurazepam in a
dose-dependent manner. This effect was associated with
aclearprolongationoftheslowerdecaycomponent(τslow,
Fig.2C) with no apparent effect on its percentage (Aslow,
Fig.2D).Zolpidemsigniﬁcantlyprolongedthemeantime
constant of mIPSC decaying phase at concentrations of
1 and 3μm (Fig.2F) and this change was related to an
increase in the percentage of the slow component with no
effect on the slow time constant (Fig.2G and H).
Flurazepam and zolpidem exert opposite effects
on amplitudes of currents elicited by low
and high [GABA]
Results presented in Figs1 and 2 conﬁrmed that in
our model both ﬂurazepam and zolpidem enhanced
amplitudes and prolonged decay of mIPSCs, although the
effects of these drugs showed some differences. To explore
the mechanism underlying such a modulation, current
responses to rapid GABA applications were measured.
Control responses to various GABA concentrations were
recorded (examples in Fig.3A–C thin lines) and a
dose–response relationship was constructed from values
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of current amplitudes normalized to the amplitude of
responses elicited by 10mm GABA measured from the
same patch (Fig.3D, in control conditions, currents
elicited by 10mm GABA had the averaged amplitude
of −789±198pA, n=17). From these recordings we
could estimate that the GABA concentration evoking a
half-maximalamplitudewascloseto100μm(Fig.3D).As
expected,currentresponsestolow[GABA](1–3μm)were
strongly potentiated both by ﬂurazepam and zolpidem
but the effect of the latter was signiﬁcantly larger at 1μm
GABA(Fig.3AandE).However,whenincreasing[GABA]
to 10 or 30μm, the current enhancement was no longer
present (Fig.3E) and for 100μm or 10mm GABA both
BDZ receptor agonists induced a signiﬁcant current
reduction (Fig.3B, C and E). These data demonstrate
that BDZ receptor agonists down modulate the responses
of neuronal GABAARs to saturating or half-saturating
[GABA], similarly to what was observed for recombinant
α1β2γ2 receptors (Mercik et al. 2007).
Figure 1. Flurazepam and zolpidem enhance the amplitude of mIPSCs
A, examples of mIPSCs recorded at −70 mV in control conditions (upper trace) and in the presence of 3 μM
ﬂurazepam (FL; lower trace). B, statistics of ﬂurazepam effect on mIPSC amplitude. C, typical cumulative histogram
for a record in control conditions (thin line) and in the presence of 3 μM ﬂurazepam (thick line). D, examples of
mIPSCs recorded at −70 mV in control conditions (upper trace) and in the presence of 3 μM zolpidem (Zol; lower
trace). E, statistics of zolpidem effect on mIPSC amplitude. F, typical cumulative histograms for control conditions
(thin line) and mIPSCs recordings in the presence of 3 μM zolpidem (thick line). Mean values were calculated from
at least n = 5 cells. ∗Signiﬁcant difference with respect to the control values.
Flurazepam and zolpidem differentially affect the
deactivation kinetics of currents elicited by low
and high [GABA]
Recordings of synaptic currents conﬁrmed that both
ﬂurazepam and zolpidem prolonged the decaying phase
of mIPSCs (Fig. 2). Since GABA synaptic transient is
very brief (Clements, 1996; Mozrzymas et al. 1999, 2003b;
Overstreetetal.2002;Mozrzymas,2004)itisbelievedthat
mIPSC decay is largely determined by the deactivation
process (time relaxation after agonist removal). It is thus
interesting to check how ﬂurazepam and zolpidem affect
the deactivation kinetics of currents evoked by different
GABA concentrations. For this purpose, currents were
elicited by GABA pulse whose duration was sufﬁcient
for the current to reach its maximum (or plateau).
For instance, at 1μm GABA, a 2s pulse was applied
(Fig.4A) and in these conditions, in 19 out of 28 cells, the
deactivation kinetics was characterized by a biexponential
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time course (τfast =191±21ms, τslow =880±82ms,
Aslow =0.24±0.03, n=19) and in 9 out of 28 cells, a
single exponential ﬁt was made (τ =288±34ms, n=9).
The mean deactivation time constant (1μm GABA, 2s
application) was: τmean =328±28ms (n=28). The
absolute values of τmean for currents recorded using this
experimentalprotocolshowedatendencytodecreasewith
GABA concentration (Fig.4B) that, as explained in detail
in the next section, appears to be related to an increasing
contribution of rapid desensitization at high [GABA].
Interestingly, both BDZ receptor agonists signiﬁcantly
slowed down the deactivation time course (for 2s
application of 1μm GABA, relative τmean =1.70±0.12,
n=5, for 3μm ﬂurazepam; 1.88±0.15, n=10, for 3μm
zolpidem, P <0.05, Fig.4A and C). The prolongation of
deactivation kinetics by these drugs resulted mainly from
the enhancement of percentage of the slow component
(data not shown). However, as shown in Fig.4C, when
increasing [GABA] the effect of BDZ receptor agonists
AB C D
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Figure 2. Flurazepam and zolpidem prolong the decaying phase of mIPSCs
A, typical averaged and superimposed mIPSCs recorded in control conditions (thin line) and in the presence of 3 μM
ﬂurazepam (thick line). B, statistics of the ﬂurazepam effect on the mean decay time constant (τmean). Flurazepam
prolongs the slow decay component (τslow, C) without affecting the percentage of this component (Aslow, D).
E, typical averaged and superimposed mIPSCs recorded in control conditions (thin line) and in the presence of
3 μM zolpidem (thick line). F, statistics of the zolpidem effect on the mean decay time constant (τmean). Zolpidem
does not affect the value of slow decay time constant (τslow, G) but increases the percentage of this component
(Aslow, H). Mean values were calculated from at least n = 5 cells. ∗Signiﬁcant difference with respect to the control
values.
on deactivation kinetics progressively decreased. For
ﬂurazepam (3μm), the prolongation of deactivation was
signiﬁcant for GABA concentrations up to 10μm and
for zolpidem (3μm)u pt o3 0μm GABA (Fig.4C). Since
current responses to high [GABA] may provide essential
informationonreceptorgating,itisimportanttodescribe
inmoredetailthedeactivationprocessforcurrentselicited
by saturating [GABA] (see also sections below). Decaying
phases of currents evoked by short pulses (1–3ms) of
10mm GABA were analysed to describe the deactivation
kinetics (alteration of application time within 1–3ms did
not affect the time course of current responses to 10mm
GABA). Decay of these currents could be well ﬁtted
with a sum of two exponentials (τfast =2.92±0.87ms,
τslow =125±11.40ms, Aslow =0.26±0.03, n=20)
and the weighted average deactivation time constant
was τmean =36.13±5.91ms (n=20). Flurazepam, at
concentration up to 3μm, had no signiﬁcant effect on
deactivation kinetics (Fig.4D and E). Interestingly, at
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10μm concentration, this BDZ signiﬁcantly prolonged
the deactivation kinetics (relative τmean =1.31±0.08,
n=8, P <0.05, Fig.4D, E) and this effect was related to a
prolongationoftheslowdeactivationcomponent(relative
τslow =1.30±0.10, P <0.05; relative τfast =1.18±0.10,
P >0.05; and relative Aslow =0.81±0.24, n=8,
P >0.05). However, zolpidem (at concentrations up
to 3 μm) had no signiﬁcant effect on the deactivation
A
B
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Figure 3. Effect of ﬂurazepam and zolpidem on current amplitudes responses strongly depend on GABA
concentration
Left column shows examples of current responses evoked in control conditions (thin lines) and in the presence of
3 μM ﬂurazepam (thick line) while middle column shows analogous examples for studies on the zolpidem effect.
A, examples of currents evoked by 1 μM GABA in control conditions (thin lines), in the presence of 3 μM ﬂurazepam
(thick line, left panel) and 3 μM zolpidem (thick line, right panel). B and C, examples of currents elicited by 100 μM
and by 10 mM GABA, respectively, in control conditions (thin line) and in the presence of ﬂurazepam (thick line,
left) and zolpidem (thick line, right). D, normalized dose–response relationship for current amplitudes in control
conditions. Duration of GABA application was sufﬁcient for current to reach the peak. Mean values were calculated
from at least n = 4 cells. E, statistics on zolpidem and ﬂurazepam effects on the amplitudes of currents evoked by
different GABA concentrations. Mean values were calculated from at least n = 8 cells. Insets above current traces
depict the time course of applied agonist. ∗Signiﬁcant difference with respect to the control values.
kinetics of currents evoked by 10mm GABA (Fig.4D
and E).
Notably, the deactivation kinetics observed following
the application of 1μm GABA (τmean =328ms, Fig.4A
and B) had a much slower time course than that for
short and saturating GABA pulses (τmean =36.13ms,
Fig.4B) and also had a dramatically stronger sensitivity
to ﬂurazepam (compare Fig.4C and E). Moreover, while
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deactivation of currents elicited by 1–3ms pulse of
10mm GABA was not affected by zolpidem, deactivation
following a long pulse of 1μm GABA was strongly
prolonged by this drug (compare Fig.4A and C with D
and E). These results indicate that both ﬂurazepam and
zolpidemmightbeinvolvedinmodulationofdeactivation
kinetics but their effects were critically dependent on
conditions in which the receptors were activated. In
particular, it seems important to elucidate how the
effects of ﬂurazepam and zolpidem depend on the time
duration of the GABA pulse and on the extent of receptor
desensitization.
Flurazepam and zolpidem affect the deactivation–
desensitization coupling differently
It is known that prolonged exposure of GABAARs to free
agonistmayresultinafavouredentryintothedesensitized
A
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Figure 4. Flurazepam and zolpidem affect the deactivation kinetics
A, examples of normalized and superimposed traces evoked by 1 μM GABA (2 s application) in control conditions
(thin lines) and in the presence of 3 μM ﬂurazepam (thick line, left) or 3 μM zolpidem (thick line, right).
B, dependence of mean deactivation time constant (τmean) on GABA concentration. Mean values were calculated
from at least n = 5 cells. C, relative mean deactivation time constants in the presence of 3 μM ﬂurazepam (black
bars) and 3 μM zolpidem (grey bars) versus GABA concentration. Mean values were calculated from at least
n = 5 cells. Note that a signiﬁcant effect of both BDZ receptor agonists is observed only for GABA concentrations
considerably below the EC50 value. D, examples of normalized responses elicited by short applications of saturating
GABA (10 mM for 3 ms) in control conditions (thin line) and in the presence of ﬂurazepam (thick lines, left and
middle for 3 and 10 μM, respectively) and 3 μM zolpidem (thick line, right). Since at 3 μM ﬂurazepam and 3 μM
zolpidem there was no visible effect on the deactivation time course, the control traces were shifted to the left
with respect to those recorded in the presence of ﬂurazepam and zolpidem. E, statistics of the ﬂurazepam and
zolpidem effect on mean deactivation time constant (τmean). Insets above current traces depict the time course of
the applied agonist. Mean values were calculated from at least n = 6 cells. ∗Signiﬁcant difference with respect to
the control values.
state and therefore the time of agonist application may
affectthedeactivationkinetics(Jones&Westbrook,1995).
Taking into account this prediction, we have checked how
time of agonist application affected deactivation kinetics
ofcurrentsevokedbyapplicationatdifferent[GABA]and
how the ensuing deactivation–desensitization coupling
is affected by ﬂurazepam and zolpidem. To assess the
deactivation–desensitization coupling at a given GABA
concentration, currents were elicited by a GABA pulse of
sufﬁcient duration to reach the peak or a plateau value
(a so called ‘short’ pulse; pulse durations are described
in the legend of Fig.5A–C) and then by a pulse at
least ﬁve times longer (‘long’ pulses, Fig.5A–C). The
averaged deactivation time constants were measured for
responsesevokedby‘long’(τmean(long))and‘short’pulses
(τmean(short)) and the ratio of these time constants is
shown in Fig.5D. Interestingly, up to 10μm GABA,
the prolongation of agonist pulse did not affect the
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Figure 5. Flurazepam and zolpidem differentially affect the deactivation–desensitization coupling
A, B and C, examples of current traces evoked by 1 μM,3 0μM and 10 mM GABA, respectively, applied for short
(thin line) and long time (thick line). The following durations of agonist applications were used at different
[GABA]: 1 μM, 2 s; 3 μM, 1 s; 10 μM, 50 ms; 30 μM, 10 ms; 100 μM, 5 ms; 10 mM, 1 ms and the respective
long applications were ﬁve times longer (see text for explanation of how short and long application times were
deﬁned). Right panels in A, B and C show the same current traces but normalized to the current value at the end of
GABA pulse. In C, the inset shows the rapid phases of current responses on an expanded time scale. Note that at
high [GABA] the deactivation following brief GABA pulse is much faster than that after a long application (mainly
due to a predominant rapid deactivation component in the former one). D, the ratio of τmean values measured for
deactivation currents following long and brief GABA applications, respectively, versus GABA concentration. Note
thatpulsedurationaffectsτmean onlyforGABAconcentrationsequalorabove30 μMatwhichrapiddesensitization
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deactivation kinetics (Fig.5D). On the contrary, starting
from a GABA concentration of 30μm, the larger [GABA]
was, the larger the impact of time duration of the agonist
pulse on the deactivation time course was (Fig.5D).
At high [GABA], a prolongation of the agonist pulse
resulted in a reduction (or even disappearance) of the
fast deactivation component (Fig.5C) giving rise to a
substantial increase in τmean (Fig.5D). Indeed, while
following 1ms pulse of 10mm GABA, there was a
predominant fast component of ∼2.6ms (see section
above and Fig.5C); after a longer pulse (10–30ms),
such a fast component was absent (Fig.5C, right panel).
Interestingly, the rapid decay component in currents
evoked by 1ms (10mm GABA) and during a long pulse
of the same [GABA] had indistinguishable fast decay
components (see inset on the expanded time scale in
Fig.5C) indicating that the apparent fast deactivation
is due to a rapid desensitization process. Indeed, as
presented in details in the next section, the value of the
fast desensitization time constant was not signiﬁcantly
different(P>0.05)fromthefastdeactivationcomponent.
The view that the fast deactivation component is due
to rapid desensitization is further supported by the
fact that the recovery in the paired-pulse experiments
with a short gap (two 1ms pulses of 10mm GABA
separated by a 5ms gap) yielded a recovery at the limit of
detection level (below 5%, data not shown). Moreover, as
already mentioned, the time courses of current responses
elicited by 10mm GABA pulses of duration between
1 and 3ms were indistinguishable (data not shown)
which is consistent with the mechanism in which even
a very short pulse (e.g. 1ms) of saturating [GABA]
is sufﬁcient to induce a profound desensitization that
determines the fast component of apparent deactivation.
However, the prolongation of deactivation process (at
high [GABA]) by increasing the pulse duration was not
only due to reduction or disappearance of the rapid
component.Forhalf-saturatingorsaturating[GABA],the
slow deactivation components were signiﬁcantly longer
than the ones following the short pulses (Fig.5E). Thus,
at high [GABA], rapid desensitization appears to play
a dual role in shaping the deactivation time course:
(i) it largely determines the fast component of apparent
deactivation and (ii) sojourns into the desensitized states
prolongtheslowcomponentofdeactivationprocess(Jones
& Westbrook. 1995).
becomes prominent. E, ratio of time constants of slow deactivation components (τslow) measured following long
and brief GABA applications, respectively, versus [GABA]. In D and E, mean values were calculated from at least
n = 8 cells. F, relative τmean for deactivation currents in the presence of 3 μM of ﬂurazepam (with respect to control
conditions) for short pulses (black bars) and for long pulses (middle hatched bars). Cross-hatched bars show the
ratios of relative τmean values measured for long and short pulses, respectively. G, analogous results as presented
in F but obtained for 3 μM of zolpidem. In F and G, mean values were calculated from at least n = 5 cells. Note
that at low [GABA] ﬂurazepam enhances the deactivation–desensitization coupling and zolpidem does not. Insets
above current traces depict the time course of applied agonist. ∗Signiﬁcant difference with respect to the control
values.
We next checked how ﬂurazepam and zolpidem
affected the deactivation–desensitization coupling
described above. As shown in Fig.5F, ﬂurazepam exerted
a signiﬁcantly stronger action on deactivation kinetics for
currents evoked by long agonist pulses but this effect was
presentonlyatlow[GABA](1and3μm).Onthecontrary,
zolpidem did not affect the deactivation–desensitization
coupling over the entire considered range of [GABA]
(Fig.5G).
Effect of ﬂurazepam and zolpidem on kinetics
of current responses elicited by saturating [GABA]
At saturating GABA concentrations, the binding step is
expected to occur much faster than the conformational
transitions between bound states. For this reason, the
time course of current responses to saturating [GABA]
is largely determined by gating properties of GABAAR.
Thus, in order to assess the impact of ﬂurazepam and
zolpidem on GABAAR gating, a series of application
protocolsforsaturating[GABA]wasemployed.Theeffect
of ﬂurazepam and zolpidem on deactivation kinetics
of currents evoked by short pulses (1–3ms) of 10mm
GABA was presented in previous sections (Figs4 and 5).
As already mentioned, the deactivation time course of
GABAergic currents has been found to strongly depend
on the desensitization kinetics (Jones & Westbrook, 1995)
andthereforeitisimportanttoexaminetheeffectsofthese
BDZ receptor agonists on the desensitization time course.
To this end, current responses were evoked by prolonged
(30–100ms) applications of saturating [GABA] (Fig.6A).
In control conditions, the desensitization time constant
(τdes) was 2.05±0.19ms (n=26) and the steady-state
to peak (ss/peak) was 0.18±0.023 (n=26). Flurazepam
at concentrations of 1–10μm had no signiﬁcant effect
either on τdes or on the steady-state to peak ratio (Fig.6B
and C). In contrast, zolpidem was found to signiﬁcantly
increase the rate but not the extent of desensitization
(at 3μm zolpidem relative τdes: 0.83±0.04, P <0.05,
and relative ss/peak: 0.89±0.07, n=10, P >0.05, Fig.6B
and C). This result appears surprising as ﬂurazepam (at
10μm) prolonged current deactivation while zolpidem
did not.
It is known that GABAARs tend to strongly accumulate
in the desensitized state even after a brief exposure
C   2007 The Authors. Journal compilation C   2007 The Physiological Society38 J. W. Mozrzymas and others J Physiol 585.1
to high [GABA] (Jones & Westbrook, 1995; see also
section on deactivation–desensitization coupling). This
phenomenon can be visualized in the paired-pulse
experiments (Fig.6D and E). The fact that the amplitude
of response to the second pulse is smaller than that for
the ﬁrst GABA application, indicates that a considerable
proportion of GABAARs accumulated in the desensitized
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Figure 6. Flurazepam and zolpidem affect the time course of responses elicited by saturating [GABA]
A, normalized and superimposed current traces evoked by prolonged application of saturating (10 mM) [GABA] in
control conditions (thin line) and in the presence of 3 μM zolpidem (thick line). B and C, statistics of ﬂurazepam and
zolpidem effects on the time constant of desensitization onset (τdes, B) and on the steady-state to peak parameter
(ss/peak, C). In B and C, mean values were calculated from at least n = 6 cells. D, examples of normalized currents
recorded in the paired-pulse experiments (3 ms applications of 10 mM GABA separated by 300 ms time interval) in
control conditions (thin line, left) and in the presence of 3 μM ﬂurazepam (thick like, middle) and 3 μM zolpidem
(thick line, right). Dashed line indicates the amplitude of response to the second pulse in control conditions.
E, statistics of ﬂurazepam and zolpidem effects on the recovery parameter R (see Methods). Mean values were
calculated from at least n = 6 cells. F, normalized and superimposed current traces evoked by saturating GABA in
control conditions (thin line) and in the presence of 3 μM zolpidem (thick line). G, statistics of the ﬂurazepam and
zolpidem effects on 10–90% rise time. Mean values were calculated from at least n = 4 cells. Insets above current
traces depict the time course of applied agonist. ∗Signiﬁcant difference with respect to the control values.
state. As shown in Fig.6D and E, both ﬂurazepam and
zolpidem signiﬁcantly reduced the recovery parameter
R (see Methods) but the effect of zolpidem was clearly
stronger (P<0.05). The reduction of recovery by these
BDZ receptor agonists might be due to an increase
in desensitization rate and/or the reduction of the
resensitization rate constants but it cannot be excluded
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that other parameters (such as, for example, unbinding
rate) could also be involved.
In control conditions, the 10–90% rise time of current
responsesevokedbyrapidapplicationof10mmGABAwas
0.23±0.01ms (n=16). Flurazepam at a concentration
up to 10μm did not signiﬁcantly affect the current onset
rate (Fig.6G). In contrast, zolpidem at a concentration
of 3μm signiﬁcantly accelerated the 10–90% rise time
(relative 10–90% rise time 0.66±0.06, n=6, P <0.05,
Fig.6F and G).
Altogether, recordings of currents elicited by various
protocols of saturating [GABA] applications revealed
that both ﬂurazepam and zolpidem affected the time
courseofrecordedresponsesalthoughtheireffectsshowed
qualitative differences.
Effect of BDZ receptor agonists on current responses
to brief applications of half-saturating [GABA]
The results presented above show that both mIPSCs
and current responses elicited by exogenous GABA
applications are potently modulated by BDZ receptor
agonists but a correlation between these effects is
not straightforward. While these compounds markedly
decreased the amplitude of current responses to 100μm
and 10mm GABA (Fig. 3), the same concentrations
of these drugs clearly increased the mIPSC amplitudes
(Fig. 1). This observation is particularly puzzling because
thepeakofsynapticGABAtransientiscommonlybelieved
to reach millimolar concentrations (Clements, 1996;
Mozrzymas et al. 1999, 2003b;O v e r s t r e e tet al. 2002;
Mozrzymas, 2004). Moreover, while both ﬂurazepam and
zolpidem prolonged mIPSC decaying phase (Fig. 2), a
moderate effect on deactivation of current responses was
observed only for 10μm ﬂurazepam (Fig. 4). There are
at least two possible explanations for these differences:
(i) activation of synaptic receptors is evoked by a GABA
transient that is considerably shorter than GABA pulses
applied using our application system, and (ii) synaptic
GABAARs are endowed with qualitatively different
properties with respect to the extrasynaptic ones that are
likely to be abundantly present in the excised patches (or
whole cells). In the present section, we shall consider the
ﬁrst possibility while the second one is discussed in the
next one. As mentioned in Methods, the shortest pulse
duration that can be reliably applied with our perfusion
system was ∼0.8–1ms. Thus, the major problem with
experimental modelling of synaptic transient is that it
may be up to one order of magnitude shorter than 1ms
(Mozrzymas et al. 1999, 2003b;O v e r s t r e e tet al. 2002;
Mozrzymas, 2004). Most importantly, such extremely
short duration of the agonist pulse makes a relatively high
(millimolar) synaptic GABA concentration considerably
distant from saturation. In practice, the amplitude of
the postsynaptic current response to a synaptic agonist
pulse is better correlated with the product of the peak
concentration and time duration of neurotransmitter
presence in the cleft rather than with the peak agonist
concentration alone (see, for example, Mozrzymas, 2004;
Barberis et al. 2004). Thus, as an attempt to qualitatively
reproduce the synaptic conditions, we have applied the
agonistfor1mswhiletheconcentrationofGABAwassetat
100μm.Inthisway,theproductofpeakconcentrationand
application time is similar to that estimated for synaptic
transient (Overstreet et al. 2002; Mozrzymas et al. 2003b;
Mozrzymas, 2004) while peak agonist concentration and
time exposure were proportionally rescaled. It is expected
that current responses to 1ms application of 100μm
GABA would result in the activation of only a portion
of receptors available in the patch because during such a
short exposure to non-saturating [GABA], only a fraction
of receptors would complete the binding step. To test this
prediction, the amplitude of response to 1ms application
of 100μm GABA was compared with that measured for
5ms exposure to the same GABA concentration (Fig.7A
and B). The application of 100μm GABA for 5ms is
sufﬁcientforcurrenttoreachitsmaximumvalue(Fig.7A,
see also Mozrzymas et al. 2003a). On average, in control
conditions, the ratio of peaks evoked by 1 and 5ms was
0.31±0.04 (n=6, Fig.7A and B) indicating that in this
case the key mechanism of non-saturation is to ‘trim’
the receptor activation by agonist removal after a short
exposure. As shown in Fig.7A and B, the peak ratios
(measuredfor1and5msGABAapplications)wereclearly
increased by both ﬂurazepam and zolpidem (0.64±0.07,
n=6 and 0.60±0.04, n=7, for 3μm ﬂurazepam and
3μmzolpidem,respectively,P <0.05).Interestingly,while
both BDZ receptor agonists decreased the amplitudes of
currents evoked by 5ms application of 100μm GABA
(Fig.7A and B, see also Fig.3C and D), the amplitudes
of currents evoked by 1ms application of the same
GABA concentrations were enhanced by ﬂurazepam and
zolpidem (Fig.7A, see dashed line). This result shows that
in conditions similar to those that presumably take place
in the synapse, BDZ receptor agonists may potentiate
the responses elicited by the same GABA concentration
for which currents evoked by longer applications are
down-regulated by these drugs (compare Figs3 and 7).
The observed increase in peak ratios for responses to 1
and 5ms of 100μm GABA in the presence of ﬂurazepam
andzolpidem(Fig.7)appearscompatiblewiththeincrease
in the binding rate by these drugs. Effective rate of agonist
binding is assumed to be proportional to the agonist
concentration (∼kon[GABA], where kon is the binding
rate) and at a non-saturating [GABA] (100μm GABA is
farfromsaturatingtheonsetrate,Mozrzymasetal.2003a;
Fig.3D) the current onset is expected to depend on the
binding rate. We therefore analysed the onset kinetics for
responsesevokedby5msapplicationof100μmGABAand
found that in control conditions, the 10–90% rise time
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was 1.82±0.06ms (n=9). The onset kinetics of these
currents was signiﬁcantly accelerated both by ﬂurazepam
and zolpidem (relative 10–90% rise time 0.88±0.07,
n=5, and 0.85±0.03, n=4, for 3μm ﬂurazepam and
3μm zolpidem, respectively, P <0.05, Fig.7C and D).
Responses of recombinant (‘synaptic’) α1β2γ2
receptors to brief applications of non-saturating
[GABA] show similar zolpidem sensitivity as mIPSCs
As already mentioned, mIPSCs and current responses to
briefGABAapplicationsmaydifferintheirBDZsensitivity
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Figure 7. Timing of responses to non-saturating [GABA] determines the impact of BDZ receptor agonist
on current amplitudes
A, examples of superimposed currents evoked by 100 μM GABA applied for 1 and 5 ms in control conditions
(thin lines, left) and in the presence of 3 μM ﬂurazepam (thick line, middle) and 3 μM zolpidem (thick line,
right). B, statistics of ﬂurazepam and zolpidem effects on amplitude ratio (amplitude of current evoked by
1 ms pulse/amplitude of current evoked by 5 ms pulse). Mean values were calculated from at least n = 6 cells.
C, examples of normalized current responses evoked by 100 μM GABA in control conditions (thin line) and in the
presence of 3 μM ﬂurazepam (thick dash–dotted line) or 3 μM zolpidem (thick line). D, statistics of ﬂurazepam and
zolpidem effects on the 10–90% rise time of currents evoked by 100 μM GABA. Mean values were calculated from
at least n = 4 cells. Insets above current traces depict the time course of applied agonist. ∗Signiﬁcant difference
with respect to the control values.
because excised patches might contain a considerable
proportion of extrasynaptic receptors characterized by
different kinetics and pharmacology with respect to
synaptic channels (e.g. Farrant & Nusser, 2005). A
functional indication for such a difference is the fact
that the time course of synaptic currents clearly differs
from that observed for current responses to brief agonist
applications (e.g. Jones & Westbrook, 1995; Mozrzymas
et al. 1999, 2003b). In order to test whether different
BDZ action on mIPSC and on current responses might
resultfromdifferencesbetweensynapticandextrasynaptic
receptors, we have repeated key protocols for currents
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mediatedbyrecombinantα1β2γ2receptors.Thisreceptor
subtype is abundantly expressed in the CNS (Whiting,
2003) and, most importantly, in several brain regions is
predominant in GABAergic synapses. As already reported
inourpreviousstudy(Merciketal.2007),bothﬂurazepam
andzolpidemreducedtheamplitudesofcurrentresponses
to saturating [GABA] by 15 and 31%, respectively, which
is close to what we report now for neurons (Fig. 3). In
the context of the BDZ effect on synaptic currents, it is
particularly interesting to repeat the protocol depicted in
Fig. 7 (brief and long application of 100μm GABA). As
shown in Fig.8A and B, the presence of 3μm zolpidem
signiﬁcantly increased the peak ratio, similarly to the case
of responses mediated by neuronal receptors (Fig. 7). The
only difference between responses mediated by neuronal
and recombinant receptors was that the activation of the
latter by application of 100μm GABA, yielded currents
characterized by a faster onset rate (10–90% rise time
A
α1 β2 γ2
CD F E
B
Figure 8. EffectsofBDZreceptoragonistsonneuronalGABAA receptorsarereproducedforrecombinant
α1β2γ2 receptors
A, examples of normalized and superimposed currents evoked by 100 μM GABA applied for 0.8 and 2.8 ms in
control conditions (thin lines, left) and in the presence of 3 μM zolpidem (thick line, right). B, statistics of the
zolpidem effect on amplitude ratio (amplitude of current evoked by 0.8 ms pulse/amplitude of current evoked by
2.8 ms pulse). Mean values were calculated from at least n = 6 cells. C, examples of currents evoked by 1 μM
GABA in control conditions (thin line) and in the presence of 3 μM zolpidem (thick line). D, statistics of zolpidem
effect on amplitude of currents evoked by 1 μM GABA. Mean value was calculated from n = 7 cells. E, normalized
and superimposed traces presented in C. A prolongation of deactivation by zolpidem (thick line) is clearly seen.
F, statistics of zolpidem effects on the mean deactivation time constant (τmean). Mean value was calculated from
n = 4 cells. Insets above current traces depict the time course of an applied agonist. ∗Signiﬁcant difference with
respect to the control values.
forα1β2γ2-mediatedcurrentswas1.33±0.13ms,n=4)
andforthisreasontheshortapplicationintheprotocolin
Fig.8A was reduced to 0.8ms.
It is known that the kinetic and pharmacological
properties of synaptic (e.g. α1β2γ2) and of extrasynaptic
GABAARs can be substantially different. While synaptic
GABAARs respond to rapid (phasic) pulses of agonist,
extrasynaptic ones experience prolonged exposures to
ambient [GABA] in a submicromollar range (e.g. Farrant
& Nusser, 2005). It is thus interesting to confront
the strong BDZ sensitivity of deactivation process in
current responses to low [GABA] recorded from neurons
to that measured from HEK cells expressing α1β2γ2
receptors. To this end we have investigated the zolpidem
(α1-preferring BDZ receptor agonist) effect on current
responses mediated by α1β2γ2 receptors and elicited by
1μmGABA.AsshowninFig.8CandD,zolpidemstrongly
enhanced the current amplitude (relative amplitude
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2.42±0.33, n=7) and this effect was similar to that
observed in neurons (Fig.4A and C). Moreover, the mean
deactivation time constant (τmean) was clearly prolonged
by zolpidem (relative τmean =1.90±0.25, n=4, Fig.8E
and F), nicely reproducing our observations in neurons
(Fig.4A and C). These experiments indicate that in the
considered model of cultured hippocampal neurons, the
BDZ sensitivity of currents elicited by exogenous GABA,
qualitatively follows the pattern observed for responses
mediated by recombinant α1β2γ2r e c e p t o r s .
Model simulations
The effects of ﬂurazepam and zolpidem on mIPSCs and
on current responses to exogenous GABA applications
suggest that these BDZ receptor agonists modulate both
binding and gating of GABAAR. A robust enhancement
of responses to 1–3μm GABA (Fig. 3) conﬁrms that
BDZs strongly up regulate the agonist binding. It might
be suggested that a similar effect could also be reproduced
byincreasingthereceptorefﬁcacy(Rusch&Forman,2005;
Downing et al. 2005; Campo-Soria et al. 2006). However,
it would lead to an increase in amplitude at saturating
[GABA], contrary to our experimental ﬁndings (Fig. 3,
see also Discussion).
Both ﬂurazepam and zolpidem clearly modulated the
time course of current responses elicited by saturating
[GABA] indicating that they affected gating properties
of neuronal GABAARs. The reduction of amplitudes
of responses evoked by saturating and half-saturating
[GABA] (Fig. 3) suggests an increased occupancy of
desensitized state(s). Enhancement of the desensitization
time constant by zolpidem (Fig.6A and B) together
with a slower recovery observed for both compounds
(Fig.6D and E) further suggest this possibility. It is
worth noting that strong reduction of the recovery by
BDZ receptor agonists (Fig.6E) could result in altered
frequencydependenceofIPSCs(Mellor&Randall,1997).
In our previous report (Mozrzymas et al. 2003b)w eh a v e
proposed that modulation of desensitization may offer a
potentmechanismofanamplituderegulationofresponses
evoked by saturating [GABA]. Clearly, interpretation
of our macroscopic data based on such a mechanism
requires a widely accepted notion that single channel
conductanceisnotaffectedbythesecompounds(Twyman
et al. 1989; Vicini et al. 1987; Rogers et al. 1994;
Perrais & Ropert, 1999; but see Eghbali et al. 1997). A
qualitatively similar enhancement of desensitization to
that induced by zolpidem (Fig.6A and B) was previously
reported for other BDZs also by Lavoie & Twyman (1996)
and Mellor & Randall (1997). The recovery process was
slowed down by both ﬂurazepam and zolpidem (Fig.6D
and E) and this effect could potentially involve enhanced
desensitization rate, slower resensitization and/or a
decrease in the unbinding rate. The enhancement of the
onset rate for currents elicited by saturating [GABA]
in the presence of zolpidem (Fig. 6) could suggest an
increase in transition rate from closed to open bound
states. However, as mentioned above, such an effect
would result in enhancement of responses to saturating
[GABA], contrary to our data. An alternative possibility
could be that the acceleration of current onset was
due to increased desensitization rate (Mozrzymas et al.
2003a). We suggest that in the case of zolpidem, a
concomitant observation of accelerated desensitization
onset, a decrease in current amplitude for responses
to saturating [GABA], acceleration of current onset
and reduced recovery in the paired-pulse experiments
(Fig. 6) indicate that this BDZ receptor agonist does
affect the desensitization kinetics. Although the impact
of ﬂurazepam was weaker, it is tempting to assume
that the major effects of both drugs (a decrease in
amplitude of current response to saturating [GABA]
and slow down in recovery) resulted from increased
occupancy in desensitized conformation(s). However, the
present data are not sufﬁcient to precisely indicate, for
example, which of potentially several desensitized states
are affected by the considered BDZ receptor agonists.
Moreover, it needs to be born in mind that alteration
of any current characteristics may potentially result
from a change in any rate constant in the considered
gating scheme because all receptor conformations are
functionallycoupled(Colquhoun,1998;Mozrzymasetal.
2003a). Nevertheless, we made an attempt to use model
simulations to interpret, at a qualitative level, our major
ﬁndings. The main goal was to consider the impact of
speciﬁc non-equilibrium conditions of synaptic receptor
activation on the susceptibility of mIPSCs to modulation
by BDZ agonists. Moreover, using this approach we tried
to evaluate to what extent differences in BDZ modulation
of mIPSCs and of current responses result from different
conditions in which these currents are activated.
Taking into account the available experimental
evidence, our strategy was to propose a minimum
requirement for BDZ effects by adapting a previously
published model. For this purpose we have used the
model proposed in Mozrzymas et al. (2003b) (Fig.9A)
in which we have slightly increased the binding rate
in control conditions because in the present study the
currents elicited by 100μm yielded currents with faster
onset. The major simplifying assumption of this model
is that it postulates only one set of fully bound states
(open,closed,desensitized).Inparticular,itisknownthat
besides the fast desensitized state included in the model,
there could be several slower desensitized components
which might additionally shape the current responses,
especially those elicited by long GABA pulses. The major
effect of BDZ was to increase (by nearly 80%, Fig. 3)
the currents evoked by 1μm GABA. Such a BDZ effect
can be easily reproduced by increasing the binding rate
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kon from 8.0 to 12.0ms−1. At saturating (10mm) and at
100μm [GABA], both BDZ receptor agonists considered
herereducedthecurrentamplitude(Fig.3)indicatingthat,
asmentionedabove,bothﬂurazepamandzolpidemfavour
the occupancy of the desensitized state. As an attempt to
model this possibility, we assumed that BDZ increases
the rate constant of entrance into the doubly bound
desensitized state (d2 from 12 to 17ms−1). The fact that
BDZs do not affect opening/closing rates (Twyman et al.
1989; Rogers et al. 1994) provides additional, although
indirect, evidence that the observed BDZs effects are due
totheiractiononthedesensitizedstate.Itmightbeargued
that a substantial modiﬁcation of desensitization kinetics
could affect the burst durations, the effect that has not
been observed by Twyman et al. (1989) and Rogers et al.
(1994). However, the impact of desensitization on the
burst durations is expected to be best manifested at high
agonist concentrations while single channel analysis in
these studies was performed for low [GABA]. Thus, the
effectofBDZsonburstdurationsathigh[GABA]remains
tobeelucidated.Thefactthatthemodelconsideredinthe
present report is oversimpliﬁed leads to some predictions
that were not supported by the experiment (e.g. an
increase in d2 would lead to prolongation of deactivation
kinetics that was not consistently conﬁrmed in the
experiment). The reason for this discrepancy is not clear.
It may be speculated that real GABAARs are endowed
with several desensitized conformations characterized by
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Figure 9. Increase in binding and desensitization rates qualitatively reproduces BDZ effects in model
simulations
A, the frame of the model in Jones & Westbrook (1995). The rate constants were adapted from Mozrzymas
et al. (2003b) with increased kon value as explained in text. Simulations of currents in control conditions were
made with the following rate constants: kon = 8.0 ms−1 mM−1, koff = 1m s −1,d 2 = 12 ms−1, r2 = 0.07 ms−1,
β2 = 3.0 ms−1, α2 = 0.4 ms−1,d 1 = 0.045 ms−1, r1 = 0.014 ms−1; β1 = 0.15 ms−1, α1 = 1.5 ms−1. The effect
of BDZ was modelled by increasing kon to 12.0 ms−1 mM−1 and d2 to 17 ms−1. Currents are simulated as a sum
of open states occupancies. B, simulated synaptic currents in control conditions (thin line) and in the presence of
BDZ (thick line). Synaptic GABA transient was modelled as exponentially decaying function: A exp(−t/τ) where
A = 1.0 mM and τ = 0.1 ms. C and D show simulations of currents elicited by short (1 ms) and longer (5 ms)
applications of 100 μM GABA in control conditions (thin lines, left) and in the presence of BDZ (thick lines, right).
Note that response to short application is enhanced by BDZ while that elicited by longer GABA pulses was reduced.
Insets above simulated traces described considered GABA application protocol.
distinct kinetics and BDZs could affect a desensitized
conformation with a slower kinetics, whose impact on
deactivation would be minor.
Synaptic currents were simulated as responses to the
exponentially decaying agonist waveform
(y(t)=Aexp(−t/τtransient),
where A=1.0mm and τtransient =0.1ms). As shown in
Fig.9B, modelling of BDZ action by increasing kon and
d2 was sufﬁcient to reproduce the increase in mIPSC
amplitude. Using the same model, we have simulated
the responses to 1 and 5ms of 100μm GABA. As
showninFig.9C,theabove-mentionedassumptionswere
sufﬁcient to qualitatively reproduce our ﬁnding that the
peak ratio for currents evoked by 1 and 5ms is clearly
increased by BDZ (Fig.7A and B). Moreover, while
the absolute value of the response to 1ms is increased
by BDZ, the response to 5ms is down regulated by
this modulator (Fig.9C and D). Thus, this simulation
further indicates that there is no qualitative contradiction
between observed enhancement of mIPSC by BDZ
(Fig. 1) and a down-regulation of response to saturating
or half-saturating [GABA] by this drug (Fig. 3).
Discussion
The major ﬁnding of the present work is that
the non-equilibrium conditions of synaptic GABAAR
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activation, dictated by a very brief synaptic agonist
transient (Clements, 1996; Mozrzymas et al. 1999, 2003b;
Overstreet et al. 2002; Mozrzymas, 2004), have a crucial
impact on IPSC sensitivity to BDZ receptor agonists. It
was puzzling that mIPSCs were enhanced by ﬂurazepam
and zolpidem while responses evoked by saturating or
half-saturating [GABA] were down-regulated by these
drugs (Figs1 and 3). This discrepancy could not result
from different GABAAR subtypes in synapses and in
excised patches (or whole cells) because a similar BDZ
effect was observed for α1β2γ2 receptors (Fig. 8; Mercik
et al. 2007) that are abundantly present in GABAergic
synapses (e.g. Farrant & Nusser, 2005). Moreover, our
experimental data (Figs7 and 8) and model simulations
(Fig.9)showthatfornon-saturating[GABA],appropriate
timing of GABA applications is sufﬁcient to reproduce
such apparently opposite BDZ effects. This reﬂects a
general rule that a very brief agonist transient renders the
IPSCsparticularlysensitivetomodulatorsaffectingGABA
binding and the larger the distance from saturation, the
largertheimpactofsuchmodiﬁers(Mozrzymasetal.1999,
2003b; Mozrzymas, 2004).
Asexplainedabove,themostparsimoniousmechanism
for observed effects of ﬂurazepam and zolpidem
is an up-regulation of binding and desensitization.
Although modulation of GABAAR gating by both
BDZ receptor agonists considered here appears most
compatible with enhancement of desensitization, there
were qualitative differences in modulation of gating by
ﬂurazepam and zolpidem. The impact of these drugs
on deactivation–desensitization coupling (Fig. 5) and
on desensitization (Fig. 6) was clearly different. Our
data are insufﬁcient to ascribe these differences to, for
example, differential modulation of distinct desensitized
conformations. Moreover, we cannot exclude that
these compounds additionally affected conformational
transitions other than desensitization (e.g. open/closed)
but for reasons presented in ‘Model simulations’ we
believe that their impact is minor. The mechanism
proposed here differs from that recently suggested by
Rusch & Forman (2005) and Downing et al. (2005), who
postulated enhancement in efﬁcacy by BDZs in
a spontaneously active GABAAR mutant. However,
mutations rendering the receptors spontaneously active
could affect also their sensitivity to BDZs. More recently,
however, Campo-Soria et al. (2006) have observed that in
oocytesexpressingultrahighlevelsofwildtypeGABAARs,
diazepaminducedadetectablecurrentthatwasconsidered
as further evidence for the enhancement of GABAAR
efﬁcacy by diazepam. Although our data are not sufﬁcient
to discriminate between these mechanisms, there are
some points that are worth pointing out. A substantial
enhancement of receptor efﬁcacy by BDZs would be
expected to result in a modiﬁcation of open and/or
closed time distributions that has not been observed
in classical single channel studies (Twyman et al. 1989;
Rogers et al. 1994). Since the peak of response depends
ontheoccupancybalanceofclosed,openanddesensitized
states, it is expected that the BDZs-induced increase in
efﬁcacy would increase the amplitude of current evoked
by saturating [GABA]. However, our experiments show
the opposite (Fig. 3). While there is a general agreement
that modulation of receptor desensitization may critically
shape the time course of GABAergic currents, the impact
of this conformation has not been considered in the
papers suggesting BDZ-induced enhancement of efﬁcacy.
Finally,wehavemadeanattempttorecordcurrentsevoked
by up to 10μm ﬂurazepam or to 3μm zolpidem but
no detectable currents were observed (in some cultures
GABAAR expression was quite high: whole-cell responses
to 1 μm G A B Aw e r ea b o v e1n Aa t−50mV with current
resolution of ∼5–10pA). It is thus possible that diazepam
mightactdifferentlythanﬂurazepamorzolpidem.Taking
altogether, in our view, the works discussed above (Rusch
& Forman, 2005; Downing et al. 2005; Campo-Soria et al.
2006)raiseaninterestingpossibilitythatBDZsmightaffect
the receptor efﬁcacy but do not exclude their effect on
binding or desensitization and the precise contributions
of these mechanisms remain to be assessed.
It is surprising that both ﬂurazepam and zolpidem
strongly slowed down the deactivation of currents evoked
by low (1–30μm) GABA (Fig. 4) while for responses to
higher [GABA] this effect was not present (except for
a subtle effect at 10μm ﬂurazepam). Importantly, this
pattern was observed both for neuronal GABAARs and
recombinant α1β2γ2 receptors (Figs3 and 8). It is still
more puzzling that the BDZ receptor agonists considered
here prolonged mIPSCs (Fig. 2), while deactivation of
currents elicited by 100μm and higher [GABA] was not
affected. Although we have no deﬁnite explanation for
thesediscrepancies,wewouldliketoproposeamechanism
that appears plausible and is compatible with all our
experimental ﬁndings. The fact that the major effects
of BDZs on amplitude and on deactivation kinetics are
observed at GABA concentration markedly lower than
the EC50 value, suggests that they require conditions in
which a considerable percentage of receptors are singly
bound. Macdonald et al. (1989) have proposed that, at
micromolar [GABA], a considerable proportion of
channel activity is due to singly bound GABAA receptors.
The increase in binding afﬁnity by BDZ would increase
the percentage of doubly bound receptors. This, in
turn, would alter the deactivation kinetics because the
rate constants of opening/closing and desensitization are
different in doubly and singly bound receptors. This
prediction is, to a smaller or larger extent, reproduced
by each model in which singly bound open states
are postulated (e.g. Macdonald et al. 1989; Jones &
Westbrook, 1995). Such a mechanism predicts that at
higher [GABA], at which fully bound GABAARs are
predominant, BDZ impact on deactivation would be
smaller. However, a clear effect of BDZs on mIPSCs
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decay kinetics (Fig. 2) remains puzzling, as synaptic
[GABA] certainly exceeds micromolar concentrations.
Assumingthatthesynapticagonistefﬁciencyisreasonably
described by the product of peak concentration and
duration of agonist exposure (Barberis et al. 2004), the
action of synaptic GABA transient would be comparable
to application of hundreds of micromoles for ∼1ms.
However, our experiments show that at 100μm GABA,
BDZs did not affect deactivation either for neuronal or
recombinant α1β2γ2 receptors. An alternative possibility
is that synaptically released agonist spills over from the
cleft and activates perisynaptic GABAARs. Clearly, GABA
spillingoverfromasynapsereachesperisynapticreceptors
at concentrations lower than in the cleft and therefore
the ensuing current is more susceptible to modulation by
BDZs. The enhancement of this current would appear as
an up-regulation of the ‘slow’ IPSC component because
of prolonged diffusion and slower kinetics due to low
[GABA].AsimilarproposalthatIPSCsarepartiallyshaped
bysubsaturating[GABA]hasbeenputforwardbyHilletal.
(1998) who studied modulation of GABAergic synaptic
currents by diethyl-lactam that affected currents evoked
by non-saturating [GABA] but had no effect on responses
tosaturating[GABA].Thereisageneralagreementthatthe
phenomenon of GABA spill-over may have a pronounced
impact on GABAergic currents, especially in the case
of intense synaptic activity (e.g. Isaacson et al. 1993;
Overstreet & Westbrook, 2003) although blockade of
GABA uptake exerts only a weak, if any, effect on mIPSCs.
Interestingly, Hill reported that the contribution of
subsaturating[GABA]toIPSCswasinsensitivetoblockade
of the GABA uptake system. Altogether, we propose that
the major mechanisms of mIPSCs modulation by BDZs
arerelatedto:(i)enhancementofthebindingratethathas
aparticularlystrongeffectinconditionsofnon-saturation
andfastagonisttransient,and(ii)enhancementofcurrent
evoked by low [GABA] spilling over from the synapse
that is manifested as a slow down of mIPSC. Although
the latter proposal is compatible with our observations,
we have no direct evidence for it and therefore, at the
present stage, it remains speculative. Moreover, kinetic
behaviourofsynapticandextrasynapticGABAA receptors
(even of the same type) might differ because of possible
modulatory post-translational processes mediated by, for
example, phosphorylation/dephosphorylation or binding
to regulatory proteins (e.g. GABARAP or gephyrine).
Contrary to our ﬁndings, Mellor & Randall (1997)
and Krampﬂ et al. (1998) reported that BDZs prolonged
deactivation kinetics of currents evoked by high [GABA].
The reason for this discrepancy is not clear. However,
in these studies the fast deactivation component was at
least one order of magnitude slower than that reported
here. This may suggest that in the protocols applied by
Mellor & Randall (1997) and Krampﬂ et al. (1998) the
fast component was not detected. Other factors, such
as differences in benzodiazepine type, cellular model or
GABA application protocols could also underlie these
different observations.
TheobservationthatBDZreceptoragonistsmightaffect
different GABAAR properties (binding and gating) is not
surprising. Walters et al. (2000) provided evidence for
two functionally distinct BDZ binding sites on α1β2γ2
receptors. It is thus possible that different sensitivities to
ﬂurazepamofcurrentsevokedby1μmGABA(Fig.3)and
on deactivation of currents evoked by saturating [GABA]
(a signiﬁcant effect only at 10μm, Fig. 4) might involve
the presence of different BDZ binding sites.
An important conclusion of this work is that the
proposed mechanisms of BDZ receptor agonist action
implicates them as potent modulators of both tonic
and phasic GABAergic currents. Qualitatively, their effect
on the tonic component appears larger, which seems
important as it is believed that tonic currents mediate
considerably larger charge transfer than the phasic ones
(Farrant & Nusser, 2005). On the other hand, it needs
to be born in mind that the tonic and phasic forms
of inhibition are functionally coupled. Indeed, ambient
[GABA] depends on network excitability while shunting
(tonic)GABAergicconductancehasamajorimpactonthe
neuronal ﬁring and therefore on synaptic signalling.
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